Preliminary Final Report June 2017
Filed with ASX · · 67 pages · English
Earlier from Syntara
- Appendix 4C - quarterly June 2017
- Pharmaxis Announces Results of Pivotal CF Clinical Trial
- Pharmaxis Set to Generate Further Euro 10m Milestone Payment
- Pharmaxis Appoints Chiesi as Bronchitol Distributor in Italy
- Appendix 4C - quarterly cash flow
Later from Syntara
- Positive Recommendation for Broader Bronchitol Access in Aus
- Boehringer Ingelheim Initiates Phase IIa Study in NASH
- Antifibrotic LOXL2 Program Clears Preclinical Development
- Boehringer Initiating Phase 2a Study Diabetic Retinopathy
- Pharmaxis Acquires Control, Increases Stake in LOXL2 Program
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara